CD39/CD73 축을 통한 T 세포 활성의 복원

본 발명은 제한없이 CD73 발현 세포를 특징으로 하는 암의 치료를 포함하는, 암을 치료하기 위해 가용성 인간 CD39의 효소 활성을 억제하는 화합물을 사용하는 방법에 관한 것이다. The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers character...

Full description

Saved in:
Bibliographic Details
Main Authors CHANTEUX STEPHANIE, PATUREL CARINE, ROSSI BENJAMIN, GOURDIN NICOLAS, PERROT IVAN
Format Patent
LanguageKorean
Published 29.05.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:본 발명은 제한없이 CD73 발현 세포를 특징으로 하는 암의 치료를 포함하는, 암을 치료하기 위해 가용성 인간 CD39의 효소 활성을 억제하는 화합물을 사용하는 방법에 관한 것이다. The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
Bibliography:Application Number: KR20207012268